Welcome to Richmond Pharmacology

The FIRST to obtain MHRA Standard and Supplementary Accreditation for two hospital based clinical trial units.

All studies conducted by Richmond Pharmacology take place within units based in two acute NHS teaching
hospitals in London, St George’s Hospital and Croydon University Hospital. Presence within these hospitals
gives Richmond Pharmacology access to consultants across numerous specialties.
This coupled with an experienced in house clinical team led by Dr Ulrike Lorch, ensure unparalleled clinical
excellence for all studies conducted by Richmond Pharmacology.

• More about our Specialist Services

• Our Featured Publications

Our Specialist Services

First In Man Studies

Uniquely based with 2 prominent NHS London hospitals and certified by the highest level of Regulatory Accreditation, Richmond Pharmacology are first in man specialists. RPL's extensive experience means they can offer a broad spectrum of first in man study services. Learn More about our First in Man Studies

Thorough QTc Study Services (TQT Studies)

All our Thorough QT Studies are in collaboration with Professor Camm, Head of Cardiac and Vascular Sciences, St George's University of London, a world renowned opinion leader in cardiological analysis. In-house expertise and experience makes Richmond Pharmacology the ideal partner for performing definitive QTc Study Solutions. Read more about our Thorough Qt Studies

Bridging Studies

We're the leading global provider of Japanese Bridging Studies. We have succesfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan. Take a look at our Bridging Studies

Patient Recruitment

Our in-house Volunteer and Patient Recruitment department is the largest of any early phase CRO in the UK. We have extensive experience in recruiting a multitude of volunteer panels. Learn more about our Patient Recruitment

Adaptive Study Design

Established as Europe's industry leaders and backed by the support of a highly experienced team of clinical pharmacologists, project managers, a world-class Scientific Advisory Board and a wide range of on-site therapeutically aligned experts, RPL is perfectly equipped for the conduct of complex studies requiring the application of the Adaptive Study Design model in, but not limited to; FTIH, TQT, Japanese and Bridging Studies.

Learn more about adaptive design for early phase clinical trials »

• Back Home

Our Featured Publications

• Rule Brittania – the advantages of conducting first-time-in-human (FTIH) studies in the UK compared to other European markets.
• Levofloxacin can be used as a positive control in QT/QTc studies in healthy subjects (paper).
• An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole.
• SKY0402 (bupivacaine) does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers.
• Lamotrigine does not prolong QTc in TQT studies in healthy subjects.
• TQT Studies: Their Impact on Drug Development and the Key Elements of a Successful TQT Study
• Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain.
• Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously.

Click here to view all of Richmond Pharmacology's Publications and Book Chapters